Authors:
Calvez, T
Biou, M
Costagliola, D
Jullien, AM
Laurian, Y
Rossi, F
Rothschild, C
Sie, P
Citation: T. Calvez et al., The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system, HAEMOPHILIA, 7(1), 2001, pp. 82-88
Citation: Bm. Rothschild et C. Rothschild, Skeletal manifestations of leprosy: Analysis of 137 patients from different clinical settings in the pre- and postmodern treatment eras, JCR-J CLIN, 7(4), 2001, pp. 228-237
Authors:
White, GC
Rosendaal, F
Aledort, LM
Lusher, JM
Rothschild, C
Ingerslev, J
Citation: Gc. White et al., Definitions in hemophilia - Recommendation of the Scientific Subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, THROMB HAEM, 85(3), 2001, pp. 560-560
Authors:
Rothschild, BM
Calderon, FL
Coppa, A
Rothschild, C
Citation: Bm. Rothschild et al., First European exposure to syphilis: The Dominican Republic at the time ofColumbian contact, CLIN INF D, 31(4), 2000, pp. 936-941
Authors:
Tout, H
Obert, B
Houllier, A
Fressinaud, E
Rothschild, C
Meyer, D
Girma, JP
Citation: H. Tout et al., Mapping and functional studies of two alloantibodies developed in patientswith type 3 von Willebrand disease, THROMB HAEM, 83(2), 2000, pp. 274-281
Authors:
Parquet, A
Laurian, Y
Rothschild, C
Navarro, R
Guerois, C
Gay, V
Durin, A
Peynet, J
Sultan, Y
Citation: A. Parquet et al., Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate, THROMB HAEM, 82(4), 1999, pp. 1247-1249
Citation: C. Rothschild, Genetic hemostasis abnormalities carrying a risk of abnormal bleeding during puberty, pregnancy, and delivery, ANN PEDIAT, 46(8), 1999, pp. 556-560